Prior art

The provided patent text for US12195773B2 does not include a "References Cited" section listing prior art patents. To fulfill the request, a live search of the USPTO database (via Google Patents as it was the source of the provided text) was performed for US12195773B2 to identify relevant prior art citations.

The priority date for US12195773B2 is December 30, 2011. Therefore, prior art under 35 U.S.C. § 102 generally includes references with an effective filing or publication date preceding this date. The following are three examples of relevant prior art identified from the "Cited by examiner" section of the US12195773B2 Google Patents page, which have effective dates prior to December 30, 2011.

Most Relevant Prior Art for US12195773B2

1. US 2011/0300619 A1

• Full Citation: US 2011/0300619 A1, "MODIFIED POLYPEPTIDE", invented by Ge Wei, H. Michael Shepard, Qiping Zhao, Robert James Connor, assigned to Halozyme, Inc.
• Publication/Filing Date: Filed June 3, 2011; Published December 8, 2011.
• Brief Description: This patent application describes modified polypeptides, specifically PH20 hyaluronidase polypeptides, designed to exhibit increased stability and/or activity. It discusses various modifications, including amino acid replacements, deletions, and insertions, to alter properties like stability under denaturing conditions such as elevated temperature, agitation, low salt, or the presence of excipients. The application also provides compositions and formulations containing these modified polypeptides.
• Potential Anticipated Claims (35 U.S.C. § 102): This reference potentially anticipates broad claims in US12195773B2 related to modified PH20 polypeptides with increased stability or activity. For example, it could anticipate claims covering "modified PH20 polypeptides that contain one or more amino acid replacements that result in a PH20 polypeptide that retains activity and/or exhibits increased or altered stability under a variety of conditions" or "modified PH20 polypeptides that contain at least one amino acid replacement in a PH20 polypeptide, whereby the modified PH20 polypeptide exhibits increased stability compared to the PH20 polypeptide not containing the amino acid replacement." Claims related to specific types of increased stability (e.g., to temperature, agitation, low salt, or excipients) could also be anticipated if broadly claimed in US12195773B2.

2. US 7,282,199 B2

• Full Citation: US 7,282,199 B2, "SOLUBLE HYALURONIDASE GLYCOSYLATION VARIANTS", invented by Kolter et al., assigned to Halozyme, Inc.
• Publication/Filing Date: Filed August 4, 2005; Granted October 16, 2007.
• Brief Description: This patent discloses soluble hyaluronidase variants, particularly human PH20 hyaluronidase (sHapH20), which have altered glycosylation patterns. These variants are characterized by increased stability (e.g., thermal stability) and/or reduced immunogenicity. The patent specifically details PH20 polypeptides with modified N-glycosylation sites.
• Potential Anticipated Claims (35 U.S.C. § 102): This patent potentially anticipates claims in US12195773B2 concerning modified PH20 polypeptides that achieve increased stability through glycosylation modifications. For instance, the definition in US12195773B2 mentions: "the modified PH20 polypeptide can be glycosylated, such as by containing at least an N-acetylglucosamine moiety linked to each of at least three asparagine (N) residues, where, for example, the three asparagine residues correspond to amino acid residues 200, 333 and 358 of SEQ ID NO:3." Claims defining modified PH20 with improved stability based on altered glycosylation, particularly at N-linked sites, could be anticipated by US7282199B2.

3. US 8,986,670 B2

• Full Citation: US 8,986,670 B2, "Hyaluronidase and formulations thereof", invented by R. James Connor, assigned to Halozyme, Inc.
• Publication/Filing Date: Claims priority to U.S. Provisional Application No. 61/511,041, filed July 24, 2011. The filing date of the granted patent is July 24, 2012, and it was granted on March 24, 2015. The earliest priority date (July 24, 2011) is prior to the December 30, 2011 priority date of US12195773B2.
• Brief Description: This patent describes stable liquid formulations of hyaluronidase, particularly PH20 hyaluronidase, which include specific stabilizing agents such as citrate and a non-ionic surfactant. The invention also encompasses methods for using these stable formulations.
• Potential Anticipated Claims (35 U.S.C. § 102): This patent could anticipate claims in US12195773B2 related to formulations of PH20 polypeptides, particularly those that address the stability of the enzyme in liquid formulations due to the presence of specific excipients or formulation conditions. For example, claims covering "compositions that contain any of the modified PH20 polypeptides provided herein" where the stability of the composition is a key feature, especially concerning stabilizing agents, could be anticipated. Claims that specify the stability of the composition at certain temperatures or over time due to formulation components might also be relevant.